Cough Frequency as a Digital Biomarker
Cough frequency is the number of coughs recorded per hour by an automated acoustic monitor. It is the rare digital measure that trials use almost exclusively as a primary endpoint.
Evidence maturity
Graded with the V3 framework: whether the sensor measures accurately, whether the algorithm has been validated against a reference standard, and whether the measure has been shown to matter clinically.
Objective counting is validated against manual listening and has carried the primary endpoint in phase three chronic cough trials, with published meaningful change thresholds. Detection accuracy in unrestricted daily life is less well characterised than validation samples suggest.
What is Cough Frequency
Cough frequency is the count of cough events over a recording period, conventionally expressed as coughs per hour and reported separately for the whole day and for waking hours. It is measured by an ambulatory monitor that records ambient sound continuously and applies an algorithm to identify cough sounds, which removes the need for the person to notice, remember or report their own coughing.
That matters because cough is a symptom people are demonstrably bad at quantifying. Severity questionnaires capture how much cough bothers someone, which is a different quantity from how often they cough, and the two correlate only moderately. Objective counting separates the two, allowing a trial to show that a treatment reduced cough events, reduced the distress they cause, or did one without the other.
How it is measured
The standard approach uses a body worn recorder with a contact or free field microphone worn for twenty four hours. Recorded audio is processed by a cough detection algorithm, and in validation work a proportion of the recording is manually counted by trained listeners as the reference standard. The Leicester Cough Monitor was the first system to demonstrate that this could be done semi automatically with acceptable agreement against human counting, and later systems have built on the same design.
Because the method depends on continuous audio capture, it carries data handling obligations that movement based measures do not. Protocols should state what audio is retained, for how long, and whether speech is discarded at the point of processing. Participants are consenting to a microphone running in their home and workplace, and that should be presented plainly rather than buried in a device description.
Clinical use
The dominant use is in refractory and unexplained chronic cough, where objective twenty four hour cough frequency has served as the primary endpoint in large randomised trials, including the phase three programme for the P2X3 receptor antagonist gefapixant. Meaningful change thresholds for objective cough frequency have been estimated, which gives trials a basis for judging whether an observed reduction matters.
In chronic respiratory disease the application is different. Domiciliary cough monitoring has been studied for predicting exacerbations in COPD, where a rise in night time cough precedes other signs of deterioration. Across both uses, cough frequency is reported alongside a validated cough specific instrument such as the Leicester Cough Questionnaire, because reducing the count without reducing the burden is an incomplete result and regulators expect both perspectives.
Regulatory status
No standalone regulatory qualification as an endpoint. Objective cough frequency has nonetheless been accepted as the primary endpoint in registered phase three programmes, which is the practical evidence of regulatory acceptability.
Limitations
Automated cough detection is imperfect and performance varies with background noise, speech, and how the microphone is positioned. Reported agreement figures usually come from controlled validation samples rather than from unrestricted daily life. Cough frequency is also highly variable between days within the same person, which means short recordings give unstable estimates and studies generally need repeated twenty four hour periods.
The measurement is intrusive in a way that step counting is not, and some participants decline or modify their behaviour when a microphone is running. Finally, dedicated hardware is required. No consumer wearable in this library counts coughs, and treating a phone based cough app as equivalent to a validated ambulatory monitor is not defensible.
References
- Birring SS, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003. pubmed.ncbi.nlm.nih.gov
- Birring SS, et al. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J. 2008. pubmed.ncbi.nlm.nih.gov
- McGarvey LP, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough. Lancet. 2022. pubmed.ncbi.nlm.nih.gov
- Schelfhout J, et al. Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough. Lung. 2022. pubmed.ncbi.nlm.nih.gov
- Crooks MG, et al. Domiciliary cough monitoring for the prediction of COPD exacerbations. Lung. 2021. pubmed.ncbi.nlm.nih.gov
Direct objective counterpart of the Leicester Cough Questionnaire, which measures the burden cough imposes rather than how often it occurs. The COPD Assessment Test and Clinical COPD Questionnaire include cough items within a broader symptom score.
Run objective cough studies with WeGuide, the all in one patient engagement platform
Collect device data and cough specific patient reported outcomes in a single study workflow.
